Dordaviprone hydrochloride is under clinical development by Chimerix and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dordaviprone hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dordaviprone hydrochloride overview
Dordaviprone hydrochloride is under development for the treatment of high-grade glioma including thalamus, meningioma, hypothalamus, brainstem, cerebellum, midbrain, or spinal cord, diffuse midline glioma, neuroendocrine tumors, diffuse intrinsic pontine glioma, pheochromocytoma-paraganglioma (PC-PG) and endometrial, prostate cancers, , relapsed or refractory acute myelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, multiple myeloma, and unspecified indication. The drug candidate is administered orally in the form of capsules. The drug candidate is developed based on cell-based molecular imaging platform. It acts by targeting JAK/STAT pathway, Akt and ERK and ClpP.
It was also under development for the treatment of non-small cell lung cancer and triple-negative breast cancer. It was also under development for the treatment of relapsed/refractory non-Hodgkin's lymphoma includes diffuse large b-cell lymphoma, mantle cell lymphoma, gliosarcoma, cutaneous T-cell lymphoma, ovarian, colorectal cancer and transformed large cell lymphoma.
Chimerix overview
Chimerix is a biopharmaceutical company that develops, discovers, and commercializes novel and oral antiviral therapeutics. The company’s pipeline product includes ONC201, ONC206, ONC212 and CMX521 drug candidates. Its products are used to treat various diseases like malignant glioma, neuroendocrine tumors, solid tumors, COVID-19 and IND-enabling studies. Its ONC201 is a clinical-stage development for H3 K27M-mutant diffuse glioma as its lead indication ONC206 for adult and pediatric patients with primary central nervous system tumors. The organization works in partnership with Oncoceutics, Inc., Cantex Pharmaceuticals, BARDA, and SymBio Pharmaceuticals. Chimerix is headquartered in Durham, North Carolina, the US.
For a complete picture of Dordaviprone hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
